CSL Behring   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: King of Prussia PA United States (2004)

Organization Overview

First Clinical Trial
2004
NCT00640289
First Marketed Drug
2009
fibrinogen (human) (RiaSTAP)
First NDA Approval
2009
fibrinogen (human) (RiaSTAP)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CSL Behring | CSL Behring - Director, Medical Affairs Cardiovascular | CSL Behring K.K. | CSL Behring LLC | CSL Innovation Pty Ltd | CSL Limited | CSL Plasma | Joshua S. Jacobs, MD | Seqirus